Fig. 3From: Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpressiona, b Waterfall plots of the best percentage change of crizotinib in target lesions at baseline in ALK-positive patients with (b) or without c-Met overexpression (a). c PFS of crizotinib in ALK-positive patients with or without c-Met overexpression; d OS of ALK-positive patients with or without c-Met overexpressionBack to article page